TNF and Crohn disease: In a recent multicenter retrospective study conducted by Kassouri et al., the outcomes of patients with late-stage Crohn’s disease (CD) who had previously failed treatment with one anti-TNF agent and subsequently received either vedolizumab or ustekinumab as a second-line therapy were reported.